DAVA freed from oxycodone liability
AVA Pharmaceuticals announced that it has settled a patent infringement suit with Impax Laboratories and Purdue Pharma regarding Impax's generic versions of Purdue's OxyContin.
Fort Lee, N.J.-based DAVA Pharmaceuticals announced that it has settled a patent infringement suit with Impax Laboratories and Purdue Pharma regarding Impax's generic versions of Purdue's OxyContin (oxycodone HCl controlled-release tablets). DAVA, its distributors, and customers were granted a full release from liability related to the sale and distribution of Impax-produced oxycodone products. Under the terms of the settlement, Impax was granted a license to sell the products through June 14, with rights to resume marketing in the near future of a limited amount of the products for a limited period of time.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
